Patents Assigned to The Institut National de la Sante et de la Recherche Medicale (INSERM)
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Detection of SHED CD31, Diagnosis of Atherothrombosis and Autoimmune Disorders, and Methods for Analyzing Signaling Pathways
    Publication number: 20170074891
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
    Type: Application
    Filed: December 16, 2014
    Publication date: March 16, 2017
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Natural killer p30 (NKp30) dysfunction and the biological applications thereof
    Patent number: 9593376
    Abstract: The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: March 14, 2017
    Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Laurence Zitvogel, Nicolas Delahaye
  • Recombinant monovalent antibodies
    Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids
    Patent number: 9572776
    Abstract: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: February 21, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Virginie Escriou, Pascal Bigey, Daniel Scherman
  • Anti-CD28 humanized antibodies
    Patent number: 9562098
    Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES
    Publication number: 20170027860
    Abstract: The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.
    Type: Application
    Filed: December 1, 2015
    Publication date: February 2, 2017
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITÉ PARIS DESCARTES
    Inventors: Francine Behar-Cohen, Elodie Bousquet
  • Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
    Patent number: 9547006
    Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: January 17, 2017
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Marie-Lise Gougeon, Manuelle Viguier, Herve Bachelez, Nicolas Fazilleau
  • Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
    Patent number: 9546402
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 17, 2017
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Hamid Azzedine, Alexis Brice, Giovanni Stevanin, Filippo Santorelli, Paola Denora
  • Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the ZFYVE26 gene or protein
    Patent number: 9522933
    Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 20, 2016
    Assignee: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Giovanni Stevanin, Sylvain Hanein, Amir Boukhris, Cyril Goizet, Elodie Martin, Alexis Brice
  • TREATMENT OF CARDIAC DISEASES WITH MODULATORS OF THE HIPPO PATHWAY
    Publication number: 20160361340
    Abstract: The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. Further provided are transgenic animals exhibiting altered expression of the atypical cadherin Fat4 and methods using said transgenic animals, or cells isolated therefrom, for the detection of compounds having therapeutic activity toward cardiac hypertrophy or regeneration. Embodiments of the present invention provide methods and composition for therapeutic intervention in cardiac hypertrophy or heart repair by modulating Fat4 and/or Amotl1 (angiomotin-like1). Treatment may include deleting Yap or administering verteporfm. Embodiments of the present invention define the molecular events linking Fat4 and Amotl1 to cardiac growth, and show that Fat4 is required to restrict cardiomyocyte hypertrophy and cardiomyocyte proliferation and that this is mediated by Amotl1.
    Type: Application
    Filed: February 11, 2015
    Publication date: December 15, 2016
    Applicants: Inetitut Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sigolene MEILHAC, Chiara RAGNI, Jean-Francois LE GARREC, Nicolas DIGUET
  • BIOACTIVE MODIFICATION OF POLY(VINYL ALCOHOL) WITH SURFACE TOPOGRAPHY AND BIOCHEMICAL CUES FOR VASCULAR GRAFT
    Publication number: 20160361462
    Abstract: Modifications of the biomaterial poly(vinyl alcohol) with surface topographical cues, attachment factors for its improved performance, and/or sustained release of vascular endothelial biochemical cue for application as a vascular graft scaffold is described. Furthermore, novel fabrication methods to pattern the poly(vinyl alcohol) hydrogel in planar film or tubular form with the topographies in the lumen are disclosed.
    Type: Application
    Filed: April 13, 2016
    Publication date: December 15, 2016
    Applicants: NATIONAL UNIVERSITY OF SINGAPORE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: King Fai Evelyn YIM, Catherine LE VISAGE, Marie Francene Arnobit CUTIONGCO, Ming Hao TAN, Seok Hong GOH
  • FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving Tau dysfunction
    Patent number: 9518995
    Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: December 13, 2016
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • High intensity focused ultrasound device with a concave segment shaped transducer for eye treatment
    Patent number: 9517359
    Abstract: A device for treatment of an ocular pathology characterized in that it comprises at least one eye ring (1) wherein the proximal end of said eye ring (1) is suitable to be applied onto the globe and a generator (2,17) to generate ultrasound beam fixed on the distal end of the eye ring (1), the generator to generate ultrasound beam presenting a concave segment shape conformed along a single curvature corresponding to a single direction wherein the concavity is designed to be tuned towards the eyeglobe.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: December 13, 2016
    Assignees: EYE TECH CARE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabrizio Romano, Cyril Lafon, Jean-Yves Chapelon, Françoise Chavrier, Alain Birer, Laurent Farcy, Philippe Chapuis
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20160346406
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: William ROSTENE, Christophe BAUDOUIN, David GODEFROY, Alexandre DENOYER
  • DIAGNOSIS OF HEREDITARY SPASTIC PARAPLEGIAS (HSP) BY DETECTION OF A MUTATION IN THE KIAA1840 GENE OR PROTEIN
    Publication number: 20160348172
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Application
    Filed: March 12, 2014
    Publication date: December 1, 2016
    Applicant: Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: Hamid AZZEDINE, Alexis BRICE, Giovanni STEVANIN, Filippo SANTORELLI, Paola DENORA
  • Production of a human beta cell line from an early post natal pancreas
    Patent number: 9493743
    Abstract: The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non-foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing to generate human Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation. They have a gene expression profile that resembles to adult beta cells. In addition, the human beta cell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignees: UNIVERCELL BIOSOLUTIONS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Paul Czernichow, Philippe Ravassard, Raphael Scharfmann
  • Method for diagnosing a hemoglobin-related disorder
    Patent number: 9494603
    Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 15, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud, Assistance Publique—Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
    Inventors: Veronique Baudin-Creuza, Corinne Vasseur, Frederic Galacteros
  • APTAMERS INHIBITING THE ENZYMATIC ACTIVITY OF THE MMP-9 PROTEIN
    Publication number: 20160326530
    Abstract: The invention relates to an aptamer that has a G-quadruplex structure and is able to inhibit the enzymatic activity of the MMP-9 protein, as well as to the dermatological and cosmetic uses thereof.
    Type: Application
    Filed: December 30, 2014
    Publication date: November 10, 2016
    Applicants: L V M H Recherche, Institut National De La Santé Et De La Recherche Médicale (INSERM)
    Inventors: Eric Dausse, Jean-Jacques Toulme, Jean Hubert Cauchard, Robin Kurfurst, Sylvianne Schnebert
  • Methods for cancer management targeting Co-029
    Patent number: 9487586
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: November 8, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix